Journal of the advanced practitioner in oncology最新文献_第3页

The Effect of Pelvic Floor Rehabilitation on Low Anterior Resection Syndrome After Colorectal Cancer Treatment. 盆底康复对结直肠癌治疗后下前切除术综合征的影响。

Journal of the advanced practitioner in oncology Pub Date : 2024-05-22 DOI: 10.6004/jadpro.2024.15.8.4

Shelby Jones, Alison Edie, Emily Troop, Joshua S Hill, Julie A Thompson

{"title":"The Effect of Pelvic Floor Rehabilitation on Low Anterior Resection Syndrome After Colorectal Cancer Treatment.","authors":"Shelby Jones, Alison Edie, Emily Troop, Joshua S Hill, Julie A Thompson","doi":"10.6004/jadpro.2024.15.8.4","DOIUrl":"10.6004/jadpro.2024.15.8.4","url":null,"abstract":"Purpose: Low anterior resection (LAR) is the preferred surgical treatment of rectosigmoid or rectal cancers. However, it is often associated with bowel dysfunction, which is termed low anterior resection syndrome (LARS). Daily bowel dysfunction symptoms have a detrimental effect on quality of life (QOL). Pelvic floor rehabilitation (PFR) can improve pelvic floor function and QOL among patients with LARS. This quality improvement (QI) project seeks to assess the prevalence of LARS and develop and incorporate PFR for the treatment and prevention of LARS.Methods: A convenience sample of 20 patients met project inclusion. Thirteen patients participated. Individuals were categorized by diagnostic risk: low risk, high risk, and established. The intervention included 1-hour PFR sessions with the physical therapist (PT) and 5 minutes of daily self-led pelvic floor muscle exercises. Outcomes questionnaires included the LARS Score and Fecal Incontinence Quality of Life (FIQOL) Scale. Data were collected both pre- and post-colorectal cancer treatment.Results: The overall prevalence of LARS was 76.9%, which was significantly higher than the retrospective cohort comparison rate of 21.8% (p < .001). The prevalence of major LARS was 89%, 83%, and 50% at the initial, second, and third sessions, respectively, representing a 44% relative decrease. Embarrassment was significantly affected among individuals with major LARS, although ongoing PFR facilitated improvement.Conclusion: PFR is a valuable adjunct therapy for LARS, with continued sessions decreasing the overall prevalence among the cohort. Major LARS negatively impacts QOL measures early on in treatment but improves with continued PFR.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib. 骨髓纤维化治疗的进展：新的Janus激酶抑制剂超越鲁索利替尼。

Journal of the advanced practitioner in oncology Pub Date : 2024-05-22 DOI: 10.6004/jadpro.2024.15.8.6

Justin Arnall, Lindsey Lyle, Donald C Moore

{"title":"Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib.","authors":"Justin Arnall, Lindsey Lyle, Donald C Moore","doi":"10.6004/jadpro.2024.15.8.6","DOIUrl":"10.6004/jadpro.2024.15.8.6","url":null,"abstract":"Myelofibrosis is a myeloproliferative neoplasm characterized by the buildup of fibrous scar tissue in the bone marrow occurring secondary to the secretion of inflammatory cytokines, leading to cytopenias, dysfunctional hematopoiesis, and constitutional symptoms. One of the pathologic mechanisms that underlies myelofibrosis is aberrant activation of the Janus kinase (JAK)-STAT pathway. Targeting the JAK-STAT pathway via JAK inhibition can lead to significant improvements in spleen volume reduction and symptom improvement in intermediate- and high-risk myelofibrosis. The first JAK inhibitor approved by the US Food & Drug Administration was ruxolitinib in 2011. Recently, there have been additional JAK inhibitors approved for myelofibrosis, including fedratinib, pacritinib, and momelotinib. The emergence of these new therapies offers additional treatment options for patients with myelofibrosis. This article reviews the pharmacology, efficacy, safety, dosing, administration, and implications for advanced practitioners of newer JAK inhibitors (fedratinib, pacritinib, and momelotinib) in the treatment of myelofibrosis.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":" ","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Growth Factor in the Setting of CAR T-Cell Therapy: To Use or Not to Use. CAR T 细胞疗法中的生长因子：用还是不用？

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.3

Cindy L Cao, Ashley Martinez, Joyce Dains

{"title":"Growth Factor in the Setting of CAR T-Cell Therapy: To Use or Not to Use.","authors":"Cindy L Cao, Ashley Martinez, Joyce Dains","doi":"10.6004/jadpro.2024.15.4.3","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.3","url":null,"abstract":"Patients undergoing chimeric antigen receptor (CAR) T-cell therapy may experience side effects including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), neutropenia, and infection. Growth factor has historically been used to treat neutropenia; however, its role in CAR T-cell therapy is not well explained. Existing data on the safety and efficacy of growth factor are conflicting. The purpose of this integrative review was to explore the safety and efficacy of growth factor in adult patients with hematologic malignancies undergoing CAR T-cell therapy. A literature review was conducted using PubMed, Cumulative Index to Nursing & Allied Health (CINAHL), and Scopus databases. A total of 2,635 articles were retrieved. Four studies were included that looked at the use of growth factor in the CAR T-cell setting. Safety outcomes evaluated included CRS, ICANS, neutropenic fever and/or infection, and neutropenia duration. Efficacy outcomes evaluated included CAR T-cell expansion and treatment response. The literature suggests that growth factor may not increase CRS prevalence, but may lead to an increased grade of CRS, namely grade 2. Growth factor administration does not have any association with ICANS toxicity, CAR T-cell expansion, or treatment response. Its use may not necessarily lead to decreased infection rates but may shorten the duration of neutropenia. Practice implications for providers working with this unique patient population include using growth factor early in the course of CAR T-cell therapy as treatment to shorten the duration of neutropenia rather than infection prophylaxis.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"253-264"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of Music Therapy as an Adjunctive Treatment in Pediatric Cancer Patients Receiving Traditional Therapies: A Systematic Review. 音乐疗法对接受传统疗法的儿童癌症患者的辅助治疗效果：系统回顾

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.4

Debra M Cole, Kaitlin Beane, Madeleine Engel, Madison Shaffer, Sarah Tartabini

{"title":"The Effect of Music Therapy as an Adjunctive Treatment in Pediatric Cancer Patients Receiving Traditional Therapies: A Systematic Review.","authors":"Debra M Cole, Kaitlin Beane, Madeleine Engel, Madison Shaffer, Sarah Tartabini","doi":"10.6004/jadpro.2024.15.4.4","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.4","url":null,"abstract":"Aim: This study aimed to analyze articles that discussed the effect of music as adjunctive therapy to traditional treatments of pediatric cancer patients compared to a control of no music therapy.Background: Cancer is a leading cause of death in children, with over 400,000 children diagnosed annually. During standard oncologic treatments, children often experience psychological and physical adverse effects. The use of music therapy can provide numerous supportive benefits to pediatric patients as adjunctive treatment in reducing psychological and physical burdens.Design: This was a systematic review of English-language articles from PubMed.Methods: Nine outcome articles were utilized in this systematic review, including quantitative and qualitative reviews of case studies, interviews, historical accounts, randomized control trials, and other systematic reviews.Results: The study found increased quality of life (QOL) involving dimensions of mood, cognition, relaxation, self-esteem, vitality, and a sense of community involving interpersonal relationships. The implementation of music therapy in pediatric oncology patients decreased stress/distress and pain. Qualitative data suggests QOL dimensions of localization and control of feelings, sense of community involving social roles and ecological health, stress, distress, and pain, improved in pediatric oncology patients receiving music therapy.Conclusion: The literature supports music therapy as a complementary treatment during traditional therapies to help decrease stress and pain in children and improve quality of life and sense of community. Therefore, music therapy as an adjunctive therapy should be implemented into standard practice.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"265-276"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High Altitude Help: Medical Emergencies in the Air. 高空帮助：空中医疗紧急情况。

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.1

Beth Faiman

引用次数: 0

Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma. 使用 31 基因表达谱检测辅助决定皮肤黑色素瘤的辅助治疗方案

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.5

Jillian Hunt

{"title":"Use of the 31-Gene Expression Profile Test to Aid in the Decision of Adjuvant Treatment of Cutaneous Melanoma.","authors":"Jillian Hunt","doi":"10.6004/jadpro.2024.15.4.5","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.5","url":null,"abstract":"Melanoma is the fifth most common cancer in the United States, with over 7,000 deaths annually. Although most patients diagnosed with early-stage (stage I or II) disease have an excellent prognosis, two out of three patients who die from melanoma were initially diagnosed in early stages. Thus, additional methods to identify which patients are at risk of poor outcomes are needed. DecisionDx-Melanoma is a 31-gene expression profile (31-GEP) molecular risk stratification test that predicts an individual's risk of recurrence or metastasis in patients with cutaneous melanoma (CM). Here, we describe a 61-year-old man who presented with a spot on his upper scalp. A biopsy confirmed malignant melanoma measuring > 3.87 mm, with ulceration and mitotic rate 2 to 3/mm2. CT, PET, and MRI scans did not reveal metastasis. Following wide local excision and sentinel lymph node biopsy, he was diagnosed with stage IIB CM. Due to the presence of high-risk features, 31-GEP testing was ordered, which revealed Class 2B (high-risk) CM. Due to the high-risk 31-GEP result, the patient was treated off-label with nivolumab for 1 year and received follow-up surveillance scans every 3 months for 3 years. At his last follow-up in April 2022, scans continued to show no recurrent or metastatic disease. The patient continues dermatologic screening every 6 months. The 31-GEP test provides valuable additional information to help clinicians make personalized, risk-based treatment and surveillance plans for patients with CM.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"277-280"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journal of the advanced practitioner in oncology Pub Date : 2024-05-01 DOI: 10.6004/jadpro.2024.15.4.2

Lindsay Dougherty, Whitney E Lewis, Meghan O'Neill, Amitabha Bhaumik, Denise D'Andrea, Andy L Johnson

{"title":"Infusion-Related Reaction Management With Amivantamab for EGFR Exon 20 Insertion Mutation NSCLC: A Practical Guide for Advanced Practitioners.","authors":"Lindsay Dougherty, Whitney E Lewis, Meghan O'Neill, Amitabha Bhaumik, Denise D'Andrea, Andy L Johnson","doi":"10.6004/jadpro.2024.15.4.2","DOIUrl":"https://doi.org/10.6004/jadpro.2024.15.4.2","url":null,"abstract":"Many targeted therapies to treat genetic mutations in non-small cell lung cancer (NSCLC) have been developed. Amivantamab (Rybrevant), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor, was approved by the US Food and Drug Administration in 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC EGFR exon 20 insertions, whose disease progressed on or after platinum-based chemotherapy. Amivantamab is administered intravenously weekly for 4 weeks, then every 2 weeks starting at Week 5, as 1,050 mg (body weight [BW] < 80 kg) or 1,400 mg (BW ≥ 80 kg), with the first dose split over 2 days. Infusion-related reactions (IRRs) are common with amivantamab and may present as chills, dyspnea, nausea, chest discomfort, and vomiting. To aid in the prevention, diagnosis, and treatment of IRRs, we evaluated infusion duration, IRR timing, and IRR severity in this post hoc analysis of patients who received amivantamab in CHRYSALIS. Infusion duration decreased over time, with a median infusion time at Cycle 1 Day 1 (C1D1) of 4.70 hours (1,050 mg) and 5.08 hours (1,400 mg), decreasing to 2.20 and 2.25 hours, respectively, by C1D22. Of the 273 IRRs, 98% occurred on C1D1 or C1D2, with median onset and time to resolution of 60 minutes. Most IRRs occurred during the infusion, were low grade, and were manageable with intervention strategies or treatment modifications. Advanced practitioners are critical in preventing, diagnosing, and managing IRRs, including educating patients and families, accurately administering infusions, prescribing premedications, and closely monitoring for IRRs.","PeriodicalId":94110,"journal":{"name":"Journal of the advanced practitioner in oncology","volume":"15 4","pages":"245-252"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142304999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2022-2023 Drug Updates: Investigational Therapeutics in the Pipeline. 2022-2023 药物更新：在研治疗药物。

Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.5

Sandra Cuellar

引用次数: 0

Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs. 多发性骨髓瘤的个性化治疗：指导治疗方案，满足患者需求。

Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.10

Beth Finley-Oliver, Rachid Baz

引用次数: 0

Shaping the Future of Oncology at JADPRO Live 2023. 在 JADPRO Live 2023 上塑造肿瘤学的未来。

Journal of the advanced practitioner in oncology Pub Date : 2024-04-01 DOI: 10.6004/jadpro.2024.15.3.1

Beth Faiman

引用次数: 0